<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T10:10:21Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10952339" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10952339</identifier>
        <datestamp>2024-03-21</datestamp>
        <setSpec>blackwellopen</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" id="bcp15661" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Br J Clin Pharmacol</journal-id>
              <journal-id journal-id-type="iso-abbrev">Br J Clin Pharmacol</journal-id>
              <journal-id journal-id-type="doi">10.1111/(ISSN)1365-2125</journal-id>
              <journal-id journal-id-type="publisher-id">BCP</journal-id>
              <journal-title-group>
                <journal-title>British Journal of Clinical Pharmacology</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0306-5251</issn>
              <issn pub-type="epub">1365-2125</issn>
              <publisher>
                <publisher-name>John Wiley and Sons Inc.</publisher-name>
                <publisher-loc>Hoboken</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10952339</article-id>
              <article-id pub-id-type="pmcid">PMC10952339</article-id>
              <article-id pub-id-type="pmc-uid">10952339</article-id>
              <article-id pub-id-type="pmid">36639145</article-id>
              <article-id pub-id-type="pmid">36639145</article-id>
              <article-id pub-id-type="doi">10.1111/bcp.15661</article-id>
              <article-id pub-id-type="publisher-id">BCP15661</article-id>
              <article-categories>
                <subj-group subj-group-type="overline">
                  <subject>Original Article</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Original Articles</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Analysis of serum microRNA‐122 in a randomized controlled trial of N‐acetylcysteine for treatment of antituberculosis drug‐induced liver injury</article-title>
                <alt-title alt-title-type="left-running-head">Moosa et al.</alt-title>
              </title-group>
              <contrib-group>
                <contrib id="bcp15661-cr-0001" contrib-type="author">
                  <name>
                    <surname>Moosa</surname>
                    <given-names>Muhammed Shiraz</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4354-3817</contrib-id>
                  <xref rid="bcp15661-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="bcp15661-cr-0002" contrib-type="author">
                  <name>
                    <surname>Russomanno</surname>
                    <given-names>Giusy</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3378-5524</contrib-id>
                  <xref rid="bcp15661-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="bcp15661-cr-0003" contrib-type="author">
                  <name>
                    <surname>Dorfman</surname>
                    <given-names>Jeffrey R.</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9938-8911</contrib-id>
                  <xref rid="bcp15661-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="bcp15661-cr-0004" contrib-type="author">
                  <name>
                    <surname>Gunter</surname>
                    <given-names>Hannah</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3027-0602</contrib-id>
                  <xref rid="bcp15661-aff-0004" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib id="bcp15661-cr-0005" contrib-type="author">
                  <name>
                    <surname>Patel</surname>
                    <given-names>Chandni</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5024-3420</contrib-id>
                  <xref rid="bcp15661-aff-0005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib id="bcp15661-cr-0006" contrib-type="author">
                  <name>
                    <surname>Costello</surname>
                    <given-names>Eithne</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0104-8992</contrib-id>
                  <xref rid="bcp15661-aff-0005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib id="bcp15661-cr-0007" contrib-type="author">
                  <name>
                    <surname>Carr</surname>
                    <given-names>Dan</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8028-4282</contrib-id>
                  <xref rid="bcp15661-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="bcp15661-cr-0008" contrib-type="author">
                  <name>
                    <surname>Maartens</surname>
                    <given-names>Gary</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3080-6606</contrib-id>
                  <xref rid="bcp15661-aff-0004" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib id="bcp15661-cr-0009" contrib-type="author">
                  <name>
                    <surname>Pirmohamed</surname>
                    <given-names>Munir</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7534-7266</contrib-id>
                  <xref rid="bcp15661-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="bcp15661-cr-0010" contrib-type="author">
                  <name>
                    <surname>Goldring</surname>
                    <given-names>Christopher</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8951-2226</contrib-id>
                  <xref rid="bcp15661-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="bcp15661-cr-0011" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Cohen</surname>
                    <given-names>Karen</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1892-4207</contrib-id>
                  <xref rid="bcp15661-aff-0004" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                  <address>
                    <email>karen.cohen@uct.ac.za</email>
                  </address>
                </contrib>
              </contrib-group>
              <aff id="bcp15661-aff-0001">
                <label>
                  <sup>1</sup>
                </label>
                <named-content content-type="organisation-division">New Somerset Hospital, Department of Medicine</named-content>
                <institution>University of Cape Town</institution>
                <city>Cape Town</city>
                <country country="ZA">South Africa</country>
              </aff>
              <aff id="bcp15661-aff-0002">
                <label>
                  <sup>2</sup>
                </label>
                <named-content content-type="organisation-division">Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology</named-content>
                <institution>University of Liverpool</institution>
                <city>Liverpool</city>
                <country country="GB">UK</country>
              </aff>
              <aff id="bcp15661-aff-0003">
                <label>
                  <sup>3</sup>
                </label>
                <named-content content-type="organisation-division">Division of Medical Virology, Department of Pathology</named-content>
                <institution>University of Stellenbosch</institution>
                <city>Cape Town</city>
                <country country="ZA">South Africa</country>
              </aff>
              <aff id="bcp15661-aff-0004">
                <label>
                  <sup>4</sup>
                </label>
                <named-content content-type="organisation-division">Division of Clinical Pharmacology, Department of Medicine</named-content>
                <institution>University of Cape Town</institution>
                <city>Cape Town</city>
                <country country="ZA">South Africa</country>
              </aff>
              <aff id="bcp15661-aff-0005">
                <label>
                  <sup>5</sup>
                </label>
                <named-content content-type="organisation-division">Department of Molecular and Clinical Cancer Medicine, Institute of Systems, Molecular and Integrative Biology</named-content>
                <institution>University of Liverpool</institution>
                <city>Liverpool</city>
                <country country="GB">UK</country>
              </aff>
              <author-notes>
                <corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Karen Cohen, Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.<break/>
Email: <email>karen.cohen@uct.ac.za</email>
<break/>
</corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>29</day>
                <month>1</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <month>6</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>29</day>
                <month>1</month>
                <year>2023</year>
              </pub-date>
              <volume>89</volume>
              <issue seq="160">6</issue>
              <issue-id pub-id-type="doi">10.1111/bcp.v89.6</issue-id>
              <fpage>1844</fpage>
              <lpage>1851</lpage>
              <history>
                <date date-type="rev-recd">
                  <day>30</day>
                  <month>12</month>
                  <year>2022</year>
                </date>
                <date date-type="received">
                  <day>24</day>
                  <month>10</month>
                  <year>2022</year>
                </date>
                <date date-type="accepted">
                  <day>04</day>
                  <month>1</month>
                  <year>2023</year>
                </date>
              </history>
              <permissions>
                <!--&#x000a9; 2023 The British Pharmacological Society-->
                <copyright-statement content-type="article-copyright">© 2023 The Authors. <italic toggle="yes">British Journal of Clinical Pharmacology</italic> published by John Wiley &amp; Sons Ltd on behalf of British Pharmacological Society.</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
                  <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="file:BCP-89-1844.pdf"/>
              <abstract>
                <sec id="bcp15661-sec-0001">
                  <title>Aim</title>
                  <p>Serum microRNA‐122 (miR‐122) is a novel biomarker for drug‐induced liver injury, with good sensitivity in the early diagnosis of paracetamol‐induced liver injury. We describe miR‐122 concentrations in participants with antituberculosis drug‐induced liver injury (AT‐DILI). We explored the relationship between miR‐122 and alanine aminotransferase (ALT) concentrations and the effect of N‐acetylcysteine (NAC) on miR‐122 concentrations.</p>
                </sec>
                <sec id="bcp15661-sec-0002">
                  <title>Methods</title>
                  <p>We included participants from a randomized placebo‐controlled trial of intravenous NAC in AT‐DILI. ALT and miR‐122 concentrations were quantified before and after infusion of NAC/placebo. We assessed correlations between ALT and miR‐122 concentrations and described changes in ALT and miR‐122 concentrations between sampling occasions.</p>
                </sec>
                <sec id="bcp15661-sec-0003">
                  <title>Results</title>
                  <p>We included 45 participants; mean age (± standard deviation) 38 (±10) years, 58% female and 91% HIV positive. The median (interquartile range) time between pre‐ and post‐infusion biomarker specimens was 68 h (47‐77 h). The median pre‐infusion ALT and miR‐122 concentrations were 420 U/L (238‐580) and 0.58 pM (0.18‐1.47), respectively. Pre‐infusion ALT and miR‐122 concentrations were correlated (Spearman's ρ = .54, <italic toggle="yes">P</italic> = .0001). Median fold‐changes in ALT and miR‐122 concentrations between sampling were 0.56 (0.43‐0.69) and 0.75 (0.23‐1.53), respectively, and were similar in the NAC and placebo groups (<italic toggle="yes">P</italic> = .40 and <italic toggle="yes">P</italic> = .68 respectively).</p>
                </sec>
                <sec id="bcp15661-sec-0004">
                  <title>Conclusions</title>
                  <p>miR‐122 concentrations in our participants with AT‐DILI were considerably higher than previously reported in healthy volunteers and in patients on antituberculosis therapy without liver injury. We did not detect an effect of NAC on miR‐122 concentrations. Further research is needed to determine the utility of miR‐122 in the diagnosis and management of AT‐DILI.</p>
                </sec>
              </abstract>
              <kwd-group kwd-group-type="author-generated">
                <kwd id="bcp15661-kwd-0001">antituberculosis drugs</kwd>
                <kwd id="bcp15661-kwd-0002">biomarkers</kwd>
                <kwd id="bcp15661-kwd-0003">liver injury</kwd>
                <kwd id="bcp15661-kwd-0004">microRNA‐122</kwd>
              </kwd-group>
              <funding-group>
                <award-group id="funding-0001">
                  <funding-source>
                    <institution-wrap>
                      <institution>South African Medical Research Council
</institution>
                      <institution-id institution-id-type="doi">10.13039/501100001322</institution-id>
                    </institution-wrap>
                  </funding-source>
                </award-group>
                <award-group id="funding-0002">
                  <funding-source>
                    <institution-wrap>
                      <institution>Academy of Medical Sciences
</institution>
                      <institution-id institution-id-type="doi">10.13039/501100000691</institution-id>
                    </institution-wrap>
                  </funding-source>
                </award-group>
              </funding-group>
              <counts>
                <fig-count count="3"/>
                <table-count count="1"/>
                <page-count count="8"/>
                <word-count count="5109"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>source-schema-version-number</meta-name>
                  <meta-value>2.0</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>June 2023</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>details-of-publishers-convertor</meta-name>
                  <meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.3.9 mode:remove_FC converted:20.03.2024</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <p content-type="self-citation">
                <mixed-citation publication-type="journal" id="bcp15661-cit-9001"><string-name><surname>Moosa</surname><given-names>MS</given-names></string-name>, <string-name><surname>Russomanno</surname><given-names>G</given-names></string-name>, <string-name><surname>Dorfman</surname><given-names>JR</given-names></string-name>, et al. <article-title>Analysis of serum microRNA‐122 in a randomized controlled trial of N‐acetylcysteine for treatment of antituberculosis drug‐induced liver injury</article-title>. <source>Br J Clin Pharmacol</source>. <year>2023</year>;<volume>89</volume>(<issue>6</issue>):<fpage>1844</fpage>‐<lpage>1851</lpage>. doi:<pub-id pub-id-type="doi">10.1111/bcp.15661</pub-id>
<pub-id pub-id-type="pmid">36639145</pub-id>
</mixed-citation>
              </p>
              <fn-group id="bcp15661-ntgp-0001">
                <fn id="bcp15661-note-0001">
                  <p>Christopher Goldring and Karen Cohen are joint senior authors.</p>
                </fn>
                <fn id="bcp15661-note-0002">
                  <p>The authors confirm that the PI for this paper is Karen Cohen and that she had direct clinical responsibility for study participants.</p>
                </fn>
                <fn id="bcp15661-note-0003">
                  <p><bold>Funding information</bold> South African Medical Research Council  Self‐Initiated Research Grant awarded to Gary Maartens and Academy of Medical Sciences, United Kingdom ‐ Newton Advanced Fellowship awarded to Karen Cohen.</p>
                </fn>
              </fn-group>
            </notes>
          </front>
          <body id="bcp15661-body-0001">
            <boxed-text position="float" content-type="box" id="bcp15661-blk-0001">
              <sec id="bcp15661-sec-0006">
                <title>What is already know about this subject?</title>
                <p>
                  <list list-type="bullet" id="bcp15661-list-0001">
                    <list-item id="bcp15661-li-0001">
                      <p>Serum microRNA (miR)‐122 is a sensitive biomarker for early detection of paracetamol‐induced liver injury.</p>
                    </list-item>
                    <list-item id="bcp15661-li-0002">
                      <p>Serum miR‐122 concentrations increase slightly in participants taking antituberculosis treatment without liver injury.</p>
                    </list-item>
                    <list-item id="bcp15661-li-0003">
                      <p>Serum miR‐122 concentrations increased markedly in participants with antituberculosis drug‐induced liver injury (AT‐DILI) in one study but decreased in another.</p>
                    </list-item>
                    <list-item id="bcp15661-li-0004">
                      <p>In a randomized controlled trial of intravenous N‐acetylcysteine (NAC) in participants with AT‐DILI, NAC did not hasten the decline of alanine aminotransferase (ALT) concentrations. The effect of N‐acetylcysteine on miR‐122 concentrations in this setting has not previously been studied.</p>
                    </list-item>
                  </list>
                </p>
              </sec>
              <sec id="bcp15661-sec-0007">
                <title>What this study adds?</title>
                <p>
                  <list list-type="bullet" id="bcp15661-list-0002">
                    <list-item id="bcp15661-li-0005">
                      <p>In our cohort drawn from a randomized controlled trial of intravenous NAC in participants with AT‐DILI, miR‐122 concentrations were markedly higher than those seen in healthy volunteers and in patients on antituberculosis treatment without liver injury.</p>
                    </list-item>
                    <list-item id="bcp15661-li-0006">
                      <p>We did not detect an effect of NAC on the change in miR‐122 concentrations observed during the first week after infusion of NAC/placebo.</p>
                    </list-item>
                    <list-item id="bcp15661-li-0007">
                      <p>We found high intra‐individual and inter‐individual variability in serum microRNA‐122 concentrations following AT‐DILI.</p>
                    </list-item>
                  </list>
                </p>
              </sec>
            </boxed-text>
            <sec id="bcp15661-sec-0008">
              <label>1</label>
              <title>INTRODUCTION</title>
              <p>Drug‐induced liver injury (DILI) is the most frequent severe adverse effect of first‐line antituberculosis therapy.<xref rid="bcp15661-bib-0001" ref-type="bibr"><sup>1</sup></xref> Antituberculosis drug‐induced liver injury (AT‐DILI) is primarily diagnosed by elevated serum alanine aminotransferase (ALT) concentrations, together with symptoms and signs of DILI.<xref rid="bcp15661-bib-0002" ref-type="bibr"><sup>2</sup></xref> However, ALT is not a specific biomarker of DILI because it may be released from tissues other than the liver (eg, skeletal muscle, kidney and heart).<xref rid="bcp15661-bib-0003" ref-type="bibr"><sup>3</sup></xref> More specific biomarkers of DILI are therefore potentially important.</p>
              <p>MicroRNAs are small, single‐stranded RNAs that regulate gene expression at a post‐transcriptional level.<xref rid="bcp15661-bib-0004" ref-type="bibr"><sup>4</sup></xref> MicroRNAs can be detected in blood as stable complexes and quantified using quantitative real‐time polymerase chain reaction (qRT‐PCR).<xref rid="bcp15661-bib-0005" ref-type="bibr"><sup>5</sup></xref> Liver injury due to drug exposure, viral hepatitis or hepatocellular carcinoma has been shown to result in altered microRNA expression profiles.<xref rid="bcp15661-bib-0006" ref-type="bibr"><sup>6</sup></xref>, <xref rid="bcp15661-bib-0007" ref-type="bibr"><sup>7</sup></xref>, <xref rid="bcp15661-bib-0008" ref-type="bibr"><sup>8</sup></xref>, <xref rid="bcp15661-bib-0009" ref-type="bibr"><sup>9</sup></xref> MicroRNA‐122 (miR‐122) accounts for 70% of hepatic microRNA<xref rid="bcp15661-bib-0010" ref-type="bibr"><sup>10</sup></xref> and plays an essential role in lipid metabolism, anti‐inflammatory and antitumorigenic mechanisms.<xref rid="bcp15661-bib-0011" ref-type="bibr"><sup>11</sup></xref> miR‐122 has been explored as a novel biomarker of paracetamol‐induced liver injury in pre‐clinical<xref rid="bcp15661-bib-0012" ref-type="bibr"><sup>12</sup></xref>, <xref rid="bcp15661-bib-0013" ref-type="bibr"><sup>13</sup></xref> and clinical studies.<xref rid="bcp15661-bib-0009" ref-type="bibr"><sup>9</sup></xref>, <xref rid="bcp15661-bib-0014" ref-type="bibr"><sup>14</sup></xref>, <xref rid="bcp15661-bib-0015" ref-type="bibr"><sup>15</sup></xref>, <xref rid="bcp15661-bib-0016" ref-type="bibr"><sup>16</sup></xref>, <xref rid="bcp15661-bib-0017" ref-type="bibr"><sup>17</sup></xref> In paracetamol‐induced liver injury, an increase in miR‐122 concentrations occurred earlier than an increase in ALT concentrations and was a sensitive test for identifying those patients who went on to develop liver injury.<xref rid="bcp15661-bib-0012" ref-type="bibr"><sup>12</sup></xref>, <xref rid="bcp15661-bib-0018" ref-type="bibr"><sup>18</sup></xref> Peak increases in serum miR‐122 concentrations correlated with later increases in serum ALT.<xref rid="bcp15661-bib-0013" ref-type="bibr"><sup>13</sup></xref>, <xref rid="bcp15661-bib-0014" ref-type="bibr"><sup>14</sup></xref>, <xref rid="bcp15661-bib-0019" ref-type="bibr"><sup>19</sup></xref> miR‐122 concentrations have also been found to be elevated in patients with nonparacetamol DILI.<xref rid="bcp15661-bib-0020" ref-type="bibr"><sup>20</sup></xref>, <xref rid="bcp15661-bib-0021" ref-type="bibr"><sup>21</sup></xref> miR‐122 is largely liver‐specific and therefore concentrations are unaltered by impaired renal function<xref rid="bcp15661-bib-0015" ref-type="bibr"><sup>15</sup></xref> and muscle injury.<xref rid="bcp15661-bib-0017" ref-type="bibr"><sup>17</sup></xref>
</p>
              <p>There are limited data on miR‐122 as a biomarker of AT‐DILI. For this study, we quantified miR‐122 concentrations in stored specimens from a randomized placebo‐controlled trial of N‐acetylcysteine (NAC) for treatment of AT‐DILI. We found that NAC administration shortened the duration of hospitalization, but time for ALT to fall below 100 U/L was similar for NAC and placebo groups.<xref rid="bcp15661-bib-0022" ref-type="bibr"><sup>22</sup></xref>
</p>
              <p>Our aims for this analysis were to describe miR‐122 concentrations in AT‐DILI, to assess correlations between ALT and miR‐122 concentrations, to describe changes in miR‐122 concentrations over time and to determine if repeat miR‐122 quantification would be more informative than ALT in detecting a biochemical response to NAC administration.</p>
            </sec>
            <sec sec-type="methods" id="bcp15661-sec-0009">
              <label>2</label>
              <title>METHODS</title>
              <sec id="bcp15661-sec-0010">
                <label>2.1</label>
                <title>Study participants</title>
                <p>Participants were drawn from a previously reported<xref rid="bcp15661-bib-0022" ref-type="bibr"><sup>22</sup></xref> randomized placebo‐controlled trial (RCT) of NAC in the management of AT‐DILI conducted in Cape Town, South Africa. NAC was dosed intravenously according to the regimen for paracetamol overdose: 150 mg/kg over 1 h, 50 mg/kg over 4 h and 100 mg/kg over 16 h. The study was a pragmatic randomized trial nested within routine clinical care at the participating hospitals. The study protocol specified that participants' ALTs be tested before the study infusion and twice weekly during hospital follow‐up. These ALT samples were generally taken by the hospital clinical care team. In addition to the monitoring of ALT concentrations for the clinical study, investigators collected blood samples for storage for future biomarker research. For this analysis, we included the subset of participants from the RCT with paired specimens stored for biomarker quantification: the first specimen taken between 24 h before and 30 min after commencement of the study infusion and the second specimen taken within 7 days after initiation of the study infusion. Blood was centrifuged within 8 h of collection, and serum was stored at −80°C. We compared baseline characteristics of the participants with paired samples, and study participants not included in this analysis to confirm that they were similar.</p>
              </sec>
              <sec id="bcp15661-sec-0011">
                <label>2.2</label>
                <title>ALT quantification</title>
                <p>ALT was quantified in stored serum using an International Federation of Clinical Chemistry recommended method. ALT and miR‐122 concentrations were determined from the same sample in each case, except for two pre‐infusion samples which were unsuitable for ALT determination; in those two cases, we used the ALT concentration from clinical records from an assay performed on the same day of the infusion. Both of these ALTs were from the samples taken within 3 h of the sample used for miR‐122 determination.</p>
              </sec>
              <sec id="bcp15661-sec-0012">
                <label>2.3</label>
                <title>MicroRNA isolation from serum</title>
                <p>For recovery of miRNA‐enriched fractions from serum, the miRNeasy Mini Kit and the RNeasy MinElute Cleanup Kit (Qiagen, Venlo, Netherlands) were used on the QIAcube automated platform (Qiagen), following manufacturer's instructions with an addition of 200 pM cel‐lin‐4 (cat. 4464066, ID MC10768; Ambion, Thermo Fisher Scientific, Waltham, MA, USA) as a spiked‐in exogenous nonhuman miRNA to monitor for the efficiency of the miRNA extraction process. Freshly isolated miRNA‐containing eluate (15 μL) was stored at −80°C.</p>
              </sec>
              <sec id="bcp15661-sec-0013">
                <label>2.4</label>
                <title>Reverse transcriptase and RT‐qPCR reactions</title>
                <p>TaqMan miRNA Assays for miR‐122 (Assay ID 002245) and cel‐lin‐4 (Assay ID 000258; Thermo Fisher Scientific) were used to perform real‐time quantitative PCR (RT‐qPCR). miRNA‐containing eluate was reverse‐transcribed using the TaqMan MicroRNA Reverse Transcription Kit (Thermo Fisher Scientific, Waltham, MA, USA) and a custom Multiplex RT Primer pool in a GeneAmp 9700 PCR System (Applied Biosystems, Foster City, CA, USA). A fixed volume of 2 μL miRNA‐containing eluate was added to an RT Master Mix containing dNTPs, RNase Inhibitor, Reverse Transcription Buffer, 75 units per reaction of MultiScribe Reverse Transcriptase and a multiplex RT primer pool consisting of primers for miR‐122 and cel‐lin‐4 (Thermo Fisher Scientific). A 1 nM synthetic miR‐122 (mirVana miRNA mimic, Assay ID MC11012; Ambion) was reverse‐transcribed together with the samples to allow the generation of a standard curve in each plate. No‐template samples were included as negative controls. Reaction conditions followed the manufacturer's instructions: annealing for 30 min at 16°C, followed by cDNA synthesis for 30 min at 42°C and denaturation for 5 min at 85°C. The resulting cDNA was diluted 1:3 with RNase‐free water and stored at −20°C until further processing.</p>
                <p>Pre‐amplification of cDNA was run on a GeneAmp 9700 PCR System (Applied Biosystems). Negative controls containing RNase‐free water instead of cDNA were included. Reaction conditions followed the manufacturer's instructions: 95°C for 10 min, 55°C for 2 min, 72°C for 2 min, followed by 12 cycles at 95°C for 15 s and 60°C for 4 min followed by enzyme inactivation at 99.9°C for 10 min. The pre‐amplified synthetic miR‐122 was serially diluted 1:10 (ranging from 1 nM to 0.1 fM) and stored at −20°C.</p>
                <p>Two microlitres of the diluted pre‐amplification product was combined with a qPCR Master Mix containing 5 μL of 2x TaqMan Universal MasterMix II without Uracil‐N glycosylase (Thermo Fisher Scientific) in a total reaction volume of 10 μL. RT‐qPCR was then performed in duplicates on an ABI ViiA 7 Thermocycler (Applied Biosystems) using a two‐step thermal cycling protocol of 95°C for 10 min followed by 40 cycles of 95°C (15 s) and 60°C (60 s) for both miR‐122 and cel‐lin‐4. Data were analysed using QuantStudio Real‐Time PCR Software v1.3. The number of copies of miR‐122 in each sample was quantified using the absolute quantification method with the standard curve generated with synthetic miR‐122 in each plate. miR‐122 levels were normalized to the level of cel‐lin‐4 to account for technical variations between samples. Then, 10% duplicates (including samples run in a separate plate) were added to each run to account for intra‐ and inter‐plate variability, and final miR‐122 copy numbers were averaged across experiments (intra‐ and inter‐assay coefficient of variation (CV) less than 5% and 10%, respectively).</p>
              </sec>
              <sec id="bcp15661-sec-0014">
                <label>2.5</label>
                <title>Statistical analysis</title>
                <p>Data were analysed using Stata SE Version 13.1 (Statacorp, College Station, TX, USA) and Microsoft Excel. We compared numerical data with a normal distribution using the Student's <italic toggle="yes">t</italic>‐test, non‐normally distributed data using the Wilcoxon rank sum test and categorical data using the Fisher's exact test. We calculated the Spearman's rank correlation coefficient (ρ) to assess correlation between ALT and miR‐122 concentrations. We calculated the CV for ALT and miR‐122 concentrations pre‐ and post‐study infusion. We log transformed ALT and miR‐122 concentrations for parametric comparative analyses. To explore change in miR‐122 and ALT concentration between samples, we calculated the ratio of post‐infusion to pre‐infusion concentration and performed a Student's <italic toggle="yes">t</italic>‐test on logged ratios to look for differences between groups. To determine the average change in ALT and miR‐122 concentrations per day, we calculated the slope between the concentration before and the concentration after study infusion. A <italic toggle="yes">P</italic> value of &lt;.05 was considered to be statistically significant throughout.</p>
              </sec>
              <sec id="bcp15661-sec-0015">
                <label>2.6</label>
                <title>Ethics</title>
                <p>The study protocol was approved by University of Cape Town Human Research Ethics Committee (HREC 087/2012 and HREC 421/2017) and the Western Cape Department of Health. Participants provided written informed consent. The trial was registered with the South African National Clinical Trials Registry (SANCTR: DOH‐27‐0414‐4719) and <ext-link xlink:href="http://clinicaltrials.gov" ext-link-type="uri"><bold>clinicaltrials.gov</bold></ext-link> (NCT02182167).</p>
              </sec>
            </sec>
            <sec sec-type="results" id="bcp15661-sec-0016">
              <label>3</label>
              <title>RESULTS</title>
              <sec id="bcp15661-sec-0017">
                <label>3.1</label>
                <title>Participant characteristics</title>
                <p>We included 45 of the 102 NAC randomized controlled trial participants from whom paired biomarker specimens had been collected within the specified time windows, 26 of these were from the NAC and 19 were from the placebo group (see Supporting Information Figure <xref rid="bcp15661-supitem-0002" ref-type="supplementary-material">S1</xref>). Baseline characteristics of the 45 included participants did not differ significantly from the 57 participants without paired specimens (see Supporting Information Table <xref rid="bcp15661-supitem-0001" ref-type="supplementary-material">S1</xref>). Four of the 45 participants with paired specimens died during study follow‐up (two in the NAC group and two in the placebo group) <italic toggle="yes">vs</italic> 10/57 participants without paired specimens (Fisher's exact <italic toggle="yes">P</italic> = .255).</p>
                <p>Participant characteristics were similar between the NAC and placebo groups in those participants with biomarker samples (Table <xref rid="bcp15661-tbl-0001" ref-type="table">1</xref>). The mean age was 38 years ± standard deviation (SD) 10, 58% were female and 91% were HIV positive. We had self‐reported ethnicity data on 31 participants, of whom 27 (87%) self‐identified as Black African.</p>
                <table-wrap position="float" id="bcp15661-tbl-0001" content-type="TABLE">
                  <label>TABLE 1</label>
                  <caption>
                    <p>Baseline characteristics and biomarker concentrations before and after study infusion in participants with antituberculosis drug‐induced liver injury randomized to intravenous N‐acetylcysteine or placebo</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <thead valign="bottom">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="bottom" rowspan="1" colspan="1"/>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">NAC (n = 26)</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Placebo (n = 19)</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Total (n = 45)</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1"><italic toggle="no">P</italic> value<xref rid="bcp15661-note-0005" ref-type="table-fn"><sup>a</sup></xref>
</th>
                      </tr>
                    </thead>
                    <tbody valign="top">
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Age, years, mean (±SD)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">38 (±12)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">38 (±7)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">38 (±10)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">.897</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Female, <italic toggle="yes">n</italic> (%)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">17 (65)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">9 (47)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">26 (58)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">.360</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Weight, kg, median (IQR)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">55 (49‐64)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">57 (45‐63)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">56 (48‐64)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">.980</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">HIV positive, <italic toggle="yes">n</italic> (%)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">22 (85)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">19 (100)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">41 (91%)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">.126</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">CD4 count (HIV positive) cells/mm<sup>3</sup>, median (IQR)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">93 (54‐277)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">54 (7‐132)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">74 (19‐161)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">.222</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Enrolment total bilirubin, μmol/L, median (IQR)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">50 (17‐91)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">74 (35‐191)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">52 (28‐117)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">.112</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Pre‐infusion ALT, U/L, median (IQR)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <p>361 (238‐580)</p>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <p>427 (238‐612)</p>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <p>420 (238‐580)</p>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">.899</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">CV (%)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">91</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">64</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">81</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Post‐infusion ALT, U/L, median (IQR)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">194 (119‐293)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">250 (111‐419)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">221 (119‐342)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">.550</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">CV (%)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">93</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">98</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">95</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Pre‐infusion miR‐122, pM, median (IQR)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.44 (0.17‐1.47)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.84 (0.31‐2.79)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.58 (0.18‐1.47)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">.251</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">CV (%)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">167</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">152</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">169</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Post‐infusion miR‐122, pM, median (IQR)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.18 (0.77‐0.94)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.33 (0.16‐0.86)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.26 (0.12‐0.86)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">.113</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">CV (%)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">214</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">145</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">207</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="bcp15661-ntgp-0002">
                    <fn id="bcp15661-note-0004">
                      <p>Abbreviations: ALT, alanine aminotransferase; CV, coefficient of variation; HIV, human immunodeficiency virus; IQR, interquartile range; SD, standard deviation.</p>
                    </fn>
                    <fn id="bcp15661-note-0005">
                      <label>
                        <sup>a</sup>
                      </label>
                      <p>Fisher's exact test for categorical variables, Student's <italic toggle="yes">t</italic>‐test for parametric data, Wilcoxon rank sum test for nonparametric data.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="bcp15661-sec-0018">
                <label>3.2</label>
                <title>Time intervals between AT‐DILI presentation, biomarker sampling and study infusion</title>
                <p>The median time from presentation with AT‐DILI to collection of the pre‐infusion sample was 2.7 days (interquartile range [IQR] 1.5‐4.1 days). This first sample was taken at a median of 0.6 h (IQR 0.2‐11 h) before study infusion commenced, and the second sample was taken at a median of 50 h (IQR 26‐73 h) after commencement of study infusion. The median time interval between paired specimens was 68 h (IQR 47‐77 h) and was similar between the NAC and placebo groups (Wilcoxon rank sum test <italic toggle="yes">P</italic> = .08).</p>
              </sec>
              <sec id="bcp15661-sec-0019">
                <label>3.3</label>
                <title>ALT and miR‐122 concentrations before study infusion</title>
                <p>The ALT and miR‐122 concentrations and CVs are summarized in Table <xref rid="bcp15661-tbl-0001" ref-type="table">1</xref>. The median ALT concentration before intravenous NAC/placebo infusion was 420 U/L (IQR 238‐580 U/L) and the median miR‐122 concentration was 0.58 pM (IQR 0.18‐1.47 pM) (Figure <xref rid="bcp15661-fig-0001" ref-type="fig">1</xref>). miR‐122 and ALT concentrations before study infusion were correlated (Spearman's <italic toggle="yes">ρ</italic> = .54, <italic toggle="yes">P</italic> = .0001); Figure <xref rid="bcp15661-fig-0002" ref-type="fig">2</xref>. The median cycle threshold (Ct) pre‐infusion was 23.1 (IQR 20.8‐24.7).</p>
                <fig position="float" fig-type="FIGURE" id="bcp15661-fig-0001">
                  <label>FIGURE 1</label>
                  <caption>
                    <p>Box and whisker plots of (A) alanine aminotransferase (ALT) and (B) microRNA‐122 (miR‐122) serum concentrations before and after study infusion in 45 participants in a randomized placebo‐controlled trial of intravenous N‐acetylcysteine (NAC) in the management of antituberculosis drug‐induced liver injury</p>
                  </caption>
                  <graphic xlink:href="BCP-89-1844-g002" position="anchor" id="jats-graphic-1"/>
                </fig>
                <fig position="float" fig-type="FIGURE" id="bcp15661-fig-0002">
                  <label>FIGURE 2</label>
                  <caption>
                    <p>Correlation of pre‐ and post‐study infusion serum alanine aminotransferase (ALT) and microRNA‐122 (miR‐122) concentrations in 45 participants with antituberculosis drug‐induced liver injury randomized to intravenous N‐acetylcysteine (NAC) or placebo</p>
                  </caption>
                  <graphic xlink:href="BCP-89-1844-g001" position="anchor" id="jats-graphic-3"/>
                </fig>
              </sec>
              <sec id="bcp15661-sec-0020">
                <label>3.4</label>
                <title>ALT and miR‐122 concentrations after study infusion</title>
                <p>Post‐infusion ALT and miR‐122 concentrations were similar in the NAC and placebo groups (see Table <xref rid="bcp15661-tbl-0001" ref-type="table">1</xref> and Figure <xref rid="bcp15661-fig-0001" ref-type="fig">1</xref>).Post‐infusion miR‐122 concentrations were correlated with ALT concentrations in both the NAC and placebo groups (Spearman's <italic toggle="yes">ρ</italic> = .42, <italic toggle="yes">P</italic> = .031 and Spearman's <italic toggle="yes">ρ</italic> = .53, <italic toggle="yes">P</italic> = .020, respectively) and when participants from both groups were analysed together (Spearman's <italic toggle="yes">ρ</italic> = .45, <italic toggle="yes">P</italic> = .002) (Figure <xref rid="bcp15661-fig-0002" ref-type="fig">2</xref>).The median Ct post‐infusion was 23.7 (IQR 22.0‐24.7).</p>
              </sec>
              <sec id="bcp15661-sec-0021">
                <label>3.5</label>
                <title>Change in ALT and miR‐122 concentrations</title>
                <p>ALT concentrations decreased between samples in 43 (96%) participants. In contrast, the magnitude and direction of change in miR‐122 concentrations varied substantially between participants, and miR‐122 concentrations increased in 16 (36%) participants (10/26 in NAC group and 6/19 in placebo group) (Figure <xref rid="bcp15661-fig-0003" ref-type="fig">3</xref>).</p>
                <fig position="float" fig-type="FIGURE" id="bcp15661-fig-0003">
                  <label>FIGURE 3</label>
                  <caption>
                    <p>Change in serum alanine aminotransferase (ALT) and microRNA‐122 (miR‐122) concentrations after study infusion in 45 participants with antituberculosis drug‐induced liver injury randomized to intravenous N‐acetylcysteine (NAC) or placebo</p>
                  </caption>
                  <graphic xlink:href="BCP-89-1844-g003" position="anchor" id="jats-graphic-5"/>
                </fig>
                <p>The median fold‐change in ALT concentrations between samples was 0.56 overall (IQR 0.43‐0.69) and was similar in the NAC and placebo groups: median 0.55 (0.39‐0.78) and 0.60 (0.46‐0.69), respectively (Wilcoxon rank sum test <italic toggle="yes">P</italic> = .40) (Supporting Information Figure <xref rid="bcp15661-supitem-0003" ref-type="supplementary-material">S2</xref>). The median fold change in miR‐122 concentrations was 0.75 (IQR 0.23‐1.53) overall and was similar in the NAC and placebo groups; median 0.78 (IQR 0.23‐1.53) and 0.54 (IQR 0.20‐1.62), respectively (Wilcoxon rank sum test <italic toggle="yes">P</italic> = .68) (Supporting Information Figure <xref rid="bcp15661-supitem-0003" ref-type="supplementary-material">S2</xref>; note that fold change value greater than 1 corresponds to an increase).</p>
              </sec>
              <sec id="bcp15661-sec-0022">
                <label>3.6</label>
                <title>Change in ALT and miR‐122 concentrations per day</title>
                <p>ALT concentrations changed a median of 0.79‐fold per day (IQR 0.75‐0.83‐fold) between the two biomarker samples. miR‐122 concentrations changed a median of 0.89‐fold per day (IQR 0.49‐1.17‐fold) between the two biomarker samples.</p>
              </sec>
            </sec>
            <sec sec-type="discussion" id="bcp15661-sec-0023">
              <label>4</label>
              <title>DISCUSSION</title>
              <p>The miR‐122 concentrations observed in our participants with AT‐DILI were much higher than those previously observed in healthy volunteers<xref rid="bcp15661-bib-0020" ref-type="bibr"><sup>20</sup></xref> or participants on antituberculosis therapy without DILI.<xref rid="bcp15661-bib-0023" ref-type="bibr"><sup>23</sup></xref> We found that serum ALT and miR‐122 concentrations were correlated at both sampling occasions in participants with AT‐DILI. ALT concentrations declined in almost all participants at the post‐infusion sampling occasion. In contrast, changes in miR‐122 concentrations were more variable, showing an increase in over a third of participants. The fold change in miR‐122 concentrations between samples did not differ between NAC and placebo arms.</p>
              <p>The median miR‐122 concentration before study infusion in our cohort was 0.58 pM, which is 10 times higher than the upper limit of normal (ULN) of the reference range for healthy volunteers derived from the European Safer and Faster Evidence based Translation (SAFE‐T) cohort, and 20 times the ULN from the Critical Path Institute's Predictive Safety Testing Consortium (PSTC) in the United States.<xref rid="bcp15661-bib-0020" ref-type="bibr"><sup>20</sup></xref> Only two of our participants had concentrations below the ULN derived from the SAFE‐T cohort, and none were below the PSTC ULN.</p>
              <p>In the ALISTER study cohort in Scotland, participants starting antituberculosis therapy without liver injury had similar miR‐122 concentrations to healthy volunteers. miR‐122 concentrations increased slightly after starting antituberculosis therapy but remained considerably lower (median 0.004 pM) than the miR‐122 concentrations observed in our participants with AT‐DILI.<xref rid="bcp15661-bib-0023" ref-type="bibr"><sup>23</sup></xref>
</p>
              <p>There are limited data on miR‐122 concentrations in patients with AT‐DILI. Two participants in the ALISTER cohort developed DILI with ALTs of 431 and 194 U/L, and miR‐122 concentrations of 0.06 and 0.34 pM, respectively. In both these participants, miR‐122 concentrations increased considerably from baseline, by 15‐ and 20‐fold, respectively. A recent Indian study by Bakshi et al found miR‐122 expression to be 75% lower in participants with AT‐DILI compared to healthy controls,<xref rid="bcp15661-bib-0024" ref-type="bibr"><sup>24</sup></xref> but miR‐122 was only sampled at enrolment and participants had less severe DILI than in our study, with a median ALT of 120 U/L. Despite these differences, the reason for the conflicting results is unclear and requires further exploration.</p>
              <p>miR‐122 concentrations varied widely between participants in our study, as did the intra‐individual change in miR‐122 between sampling occasions. In the absence of other clinical evidence, it is unclear whether these changes in miR‐122 concentrations indicate worsening or improvement of the liver injury or merely reflect high intra‐ and inter‐individual variability. In the PSTC healthy volunteer cohort who were sampled repeatedly over 3 weeks, both inter‐subject and intra‐subject coefficients of variation for miR‐122 were high, at 91% and 94%, respectively.<xref rid="bcp15661-bib-0020" ref-type="bibr"><sup>20</sup></xref> Intra‐individual variability was particularly high in Black participants.<xref rid="bcp15661-bib-0020" ref-type="bibr"><sup>20</sup></xref> A North American healthy volunteer cohort also found high intra‐ and inter‐donor variability in miR‐122 expression, particularly in participants who identified as non‐Caucasian.<xref rid="bcp15661-bib-0025" ref-type="bibr"><sup>25</sup></xref> Inter‐individual variability poses challenges to defining cut‐offs for abnormal elevation of miR‐122. Intra‐individual variability complicates interpretation of changes observed in miR‐122 concentration over time. Inter‐individual and intra‐individual variability may therefore limit utility of miR‐122 as a biomarker in diagnosing AT‐DILI and monitoring AT‐DILI progression or recovery.</p>
              <p>We observed an increase in miR‐122 concentrations between the two sampling occasions in a third of our study participants. The hepatocellular injury in AT‐DILI<xref rid="bcp15661-bib-0026" ref-type="bibr"><sup>26</sup></xref> may be more sustained than injury due to oxidative stress injury in paracetamol overdose, and miR‐122 may therefore decline more slowly in AT‐DILI. Even among studies of paracetamol‐induced hepatotoxicity, there are some that describe increased miR‐122 concentrations from 3 to 14 days after DILI onset.<xref rid="bcp15661-bib-0015" ref-type="bibr"><sup>15</sup></xref>, <xref rid="bcp15661-bib-0017" ref-type="bibr"><sup>17</sup></xref>
</p>
              <p>Our study has limitations. We only included RCT participants with two biomarker samples (approximately half of the cohort), which may have introduced selection bias. However, baseline characteristics and liver biochemistry did not differ substantially between those RCT participants included in this study and those not included. HIV prevalence was high in our cohort and therefore our findings may not be generalizable to other populations with lower HIV prevalence. We only quantified miR‐122 at two time points. We did not have a control group without AT‐DILI drawn from the same population to allow for comparison. Different quantification and normalization methods used in different studies may influence comparisons between our results and results from other studies.</p>
            </sec>
            <sec sec-type="conclusions" id="bcp15661-sec-0024">
              <label>5</label>
              <title>CONCLUSION</title>
              <p>miR‐122 concentrations were markedly higher in our cohort of AT‐DILI than previously observed in healthy controls and in participants on antituberculosis therapy without liver injury. miR‐122 may therefore be a useful biomarker to diagnose AT‐DILI in this population. However, high intra‐individual and inter‐individual variability in miR‐122 concentrations may limit its utility. To characterize miR‐122 concentrations prior to liver injury onset and in early AT‐DILI, a large prospective cohort study collecting repeated samples for biomarker quantification from patients on antituberculosis therapy, with frequent clinical review, would be required because AT‐DILI occurs in a small subset of patients on antituberculosis therapy. Further larger studies monitoring miR‐122 over the full course of recovery from AT‐DILI are required to characterize changes in this biomarker over time, and associations between concentrations observed and outcomes.</p>
            </sec>
            <sec sec-type="COI-statement" id="bcp15661-sec-0025">
              <title>COMPETING INTERESTS</title>
              <p>All authors declare that they have no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work. MP has received partnership funding for the following: MRC Clinical Pharmacology Training Scheme (co‐funded by MRC and Roche, UCB, Eli Lilly and Novartis) and a PhD studentship jointly funded by EPSRC and AstraZeneca. He also has unrestricted educational grant support for the UK Pharmacogenetics and Stratified Medicine Network from Bristol‐Myers Squibb. He has developed an HLA genotyping panel with MC Diagnostics but does not benefit financially from this. He is part of the IMI Consortium ARDAT (<ext-link xlink:href="http://www.ardat.org" ext-link-type="uri">www.ardat.org</ext-link>). None of this funding has been used for the current paper.</p>
            </sec>
            <sec sec-type="conclusions" id="bcp15661-sec-0026">
              <title>CONTRIBUTORS</title>
              <p>Muhammed Shiraz Moosa, Karen Cohen, Gary Maartens, Dan Carr and Munir Pirmohamed conceived and designed the study. Giusy Russomanno, Chandni Patel, Eithne Costello and Christopher Goldring were responsible for performance and oversight of miR‐122 assays and interpretation of laboratory results. Christopher Goldring, Karen Cohen and Jeffrey R. Dorfman formulated the data analysis strategy. Muhammed Shiraz Moosa and Jeffrey R. Dorfman analysed data. Muhammed Shiraz Moosa wrote the first draft of the manuscript. All authors reviewed the manuscript and contributed to revising and finalizing the manuscript.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supporting information</title>
              <supplementary-material id="bcp15661-supitem-0001" position="float" content-type="local-data">
                <caption>
                  <p><bold>TABLE S1.</bold> Baseline characteristics of participants with and without paired pre‐infusion and post‐infusion miR‐122 samples from a randomized trial of N‐ acetylcysteine in the treatment of antituberculosis drug‐induced liver injury</p>
                </caption>
                <media xlink:href="BCP-89-1844-s002.pdf"/>
              </supplementary-material>
              <supplementary-material id="bcp15661-supitem-0002" position="float" content-type="local-data">
                <caption>
                  <p><bold>FIGURE S1.</bold> The study design and timing of blood samples for alanine aminotransferase (ALT) and microRNA‐122 (miR‐122) quantification in a randomized placebo‐controlled trial of intravenous N‐acetylcysteine (NAC) in the management of antituberculosis drug‐induced liver injury.</p>
                </caption>
                <media xlink:href="BCP-89-1844-s001.pdf"/>
              </supplementary-material>
              <supplementary-material id="bcp15661-supitem-0003" position="float" content-type="local-data">
                <caption>
                  <p><bold>FIGURE S2.</bold> Ratio of post‐study infusion to pre‐study infusion serum alanine aminotransferase (ALT) and microRNA‐122 (miR‐122) concentrations in 45 participants with antituberculosis drug‐induced liver injury randomized to intravenous N‐acetylcysteine (NAC) or placebo</p>
                </caption>
                <media xlink:href="BCP-89-1844-s003.pdf"/>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <sec sec-type="data-availability" id="bcp15661-sec-0028">
              <title>DATA AVAILABILITY STATEMENT</title>
              <p>The data that support the findings of this study are stored in a controlled access repository and are not openly available due to reasons of sensitivity and patient confidentiality. Data are available from the corresponding author (Karen Cohen) upon reasonable request.</p>
            </sec>
            <ref-list id="bcp15661-bibl-0001" content-type="cited-references">
              <title>REFERENCES</title>
              <ref id="bcp15661-bib-0001">
                <label>1</label>
                <mixed-citation publication-type="journal" id="bcp15661-cit-0002"><string-name><surname>Tostmann</surname><given-names>A</given-names></string-name>, <string-name><surname>Boeree</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Aarnoutse</surname><given-names>RE</given-names></string-name>, <string-name><surname>de Lange</surname><given-names>WC</given-names></string-name>, <string-name><surname>van der Ven</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Dekhuijzen</surname><given-names>R</given-names></string-name>. <article-title>Antituberculosis drug‐induced hepatotoxicity: concise up‐to‐date review</article-title>. <source>J Gastroenterol Hepatol</source>. <year>2008</year>;<volume>23</volume>(<issue>2</issue>):<fpage>192</fpage>‐<lpage>202</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1440-1746.2007.05207.x</pub-id>
<pub-id pub-id-type="pmid">17995946</pub-id>
</mixed-citation>
              </ref>
              <ref id="bcp15661-bib-0002">
                <label>2</label>
                <mixed-citation publication-type="journal" id="bcp15661-cit-0003"><string-name><surname>Saukkonen</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Cohn</surname><given-names>DL</given-names></string-name>, <string-name><surname>Jasmer</surname><given-names>RM</given-names></string-name>, et al. <article-title>An official ATS statement: hepatotoxicity of antituberculosis therapy</article-title>. <source>Am J Respir Crit Care Med</source>. <year>2006</year>;<volume>174</volume>(<issue>8</issue>):<fpage>935</fpage>‐<lpage>952</lpage>. doi:<pub-id pub-id-type="doi">10.1164/rccm.200510-1666ST</pub-id>
<pub-id pub-id-type="pmid">17021358</pub-id>
</mixed-citation>
              </ref>
              <ref id="bcp15661-bib-0003">
                <label>3</label>
                <mixed-citation publication-type="journal" id="bcp15661-cit-0004"><string-name><surname>Lindblom</surname><given-names>P</given-names></string-name>, <string-name><surname>Rafter</surname><given-names>I</given-names></string-name>, <string-name><surname>Copley</surname><given-names>C</given-names></string-name>, et al. <article-title>Isoforms of alanine aminotransferases in human tissues and serum‐‐differential tissue expression using novel antibodies</article-title>. <source>Arch Biochem Biophys</source>. <year>2007</year>;<volume>466</volume>(<issue>1</issue>):<fpage>66</fpage>‐<lpage>77</lpage>.<pub-id pub-id-type="pmid">17826732</pub-id>
</mixed-citation>
              </ref>
              <ref id="bcp15661-bib-0004">
                <label>4</label>
                <mixed-citation publication-type="journal" id="bcp15661-cit-0005"><string-name><surname>Bartel</surname><given-names>DP</given-names></string-name>. <article-title>MicroRNAs: genomics, biogenesis, mechanism, and function</article-title>. <source>Cell</source>. <year>2004</year>;<volume>116</volume>(<issue>2</issue>):<fpage>281</fpage>‐<lpage>297</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0092-8674(04)00045-5</pub-id>
<pub-id pub-id-type="pmid">14744438</pub-id>
</mixed-citation>
              </ref>
              <ref id="bcp15661-bib-0005">
                <label>5</label>
                <mixed-citation publication-type="journal" id="bcp15661-cit-0006"><string-name><surname>Kozomara</surname><given-names>A</given-names></string-name>, <string-name><surname>Griffiths‐Jones</surname><given-names>S</given-names></string-name>. <article-title>miRBase: annotating high confidence microRNAs using deep sequencing data</article-title>. <source>Nucleic Acids Res</source>. <year>2014</year>;<volume>42</volume>(<issue>Database issue</issue>):<fpage>D68</fpage>‐<lpage>D73</lpage>. doi:<pub-id pub-id-type="doi">10.1093/nar/gkt1181</pub-id>
<pub-id pub-id-type="pmid">24275495</pub-id>
</mixed-citation>
              </ref>
              <ref id="bcp15661-bib-0006">
                <label>6</label>
                <mixed-citation publication-type="journal" id="bcp15661-cit-0007"><string-name><surname>Szabo</surname><given-names>G</given-names></string-name>, <string-name><surname>Bala</surname><given-names>S</given-names></string-name>. <article-title>MicroRNAs in liver disease</article-title>. <source>Nat Rev Gastroenterol Hepatol</source>. <year>2013</year>;<volume>10</volume>(<issue>9</issue>):<fpage>542</fpage>‐<lpage>552</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nrgastro.2013.87</pub-id>
<pub-id pub-id-type="pmid">23689081</pub-id>
</mixed-citation>
              </ref>
              <ref id="bcp15661-bib-0007">
                <label>7</label>
                <mixed-citation publication-type="journal" id="bcp15661-cit-0008"><string-name><surname>Xu</surname><given-names>J</given-names></string-name>, <string-name><surname>Wu</surname><given-names>C</given-names></string-name>, <string-name><surname>Che</surname><given-names>X</given-names></string-name>, et al. <article-title>Circulating microRNAs, miR‐21, miR‐122, and miR‐223, in patients with hepatocellular carcinoma or chronic hepatitis</article-title>. <source>Mol Carcinog</source>. <year>2011</year>;<volume>50</volume>(<issue>2</issue>):<fpage>136</fpage>‐<lpage>142</lpage>. doi:<pub-id pub-id-type="doi">10.1002/mc.20712</pub-id>
<pub-id pub-id-type="pmid">21229610</pub-id>
</mixed-citation>
              </ref>
              <ref id="bcp15661-bib-0008">
                <label>8</label>
                <mixed-citation publication-type="journal" id="bcp15661-cit-0009"><string-name><surname>Zhang</surname><given-names>H</given-names></string-name>, <string-name><surname>Li</surname><given-names>QY</given-names></string-name>, <string-name><surname>Guo</surname><given-names>ZZ</given-names></string-name>, et al. <article-title>Serum levels of microRNAs can specifically predict liver injury of chronic hepatitis B</article-title>. <source>World J Gastroenterol</source>. <year>2012</year>;<volume>18</volume>(<issue>37</issue>):<fpage>5188</fpage>‐<lpage>5196</lpage>. doi:<pub-id pub-id-type="doi">10.3748/wjg.v18.i37.5188</pub-id>
<pub-id pub-id-type="pmid">23066312</pub-id>
</mixed-citation>
              </ref>
              <ref id="bcp15661-bib-0009">
                <label>9</label>
                <mixed-citation publication-type="journal" id="bcp15661-cit-0010"><string-name><surname>Krauskopf</surname><given-names>J</given-names></string-name>, <string-name><surname>Caiment</surname><given-names>F</given-names></string-name>, <string-name><surname>Claessen</surname><given-names>SM</given-names></string-name>, et al. <article-title>Application of high‐throughput sequencing to circulating microRNAs reveals novel biomarkers for drug‐induced liver injury</article-title>. <source>Toxicol Sci</source>. <year>2015</year>;<volume>143</volume>(<issue>2</issue>):<fpage>268</fpage>‐<lpage>276</lpage>. doi:<pub-id pub-id-type="doi">10.1093/toxsci/kfu232</pub-id>
<pub-id pub-id-type="pmid">25359176</pub-id>
</mixed-citation>
              </ref>
              <ref id="bcp15661-bib-0010">
                <label>10</label>
                <mixed-citation publication-type="journal" id="bcp15661-cit-0011"><string-name><surname>Chang</surname><given-names>J</given-names></string-name>, <string-name><surname>Nicolas</surname><given-names>E</given-names></string-name>, <string-name><surname>Marks</surname><given-names>D</given-names></string-name>, et al. <article-title>miR‐122, a mammalian liver‐specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT‐1</article-title>. <source>RNA Biol</source>. <year>2004</year>;<volume>1</volume>(<issue>2</issue>):<fpage>106</fpage>‐<lpage>113</lpage>. doi:<pub-id pub-id-type="doi">10.4161/rna.1.2.1066</pub-id>
<pub-id pub-id-type="pmid">17179747</pub-id>
</mixed-citation>
              </ref>
              <ref id="bcp15661-bib-0011">
                <label>11</label>
                <mixed-citation publication-type="journal" id="bcp15661-cit-0012"><string-name><surname>Hsu</surname><given-names>SH</given-names></string-name>, <string-name><surname>Wang</surname><given-names>B</given-names></string-name>, <string-name><surname>Kota</surname><given-names>J</given-names></string-name>, et al. <article-title>Essential metabolic, anti‐inflammatory, and anti‐tumorigenic functions of miR‐122 in liver</article-title>. <source>J Clin Invest</source>. <year>2012</year>;<volume>122</volume>(<issue>8</issue>):<fpage>2871</fpage>‐<lpage>2883</lpage>. doi:<pub-id pub-id-type="doi">10.1172/JCI63539</pub-id>
<pub-id pub-id-type="pmid">22820288</pub-id>
</mixed-citation>
              </ref>
              <ref id="bcp15661-bib-0012">
                <label>12</label>
                <mixed-citation publication-type="journal" id="bcp15661-cit-0013"><string-name><surname>Wang</surname><given-names>K</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>S</given-names></string-name>, <string-name><surname>Marzolf</surname><given-names>B</given-names></string-name>, et al. <article-title>Circulating microRNAs, potential biomarkers for drug‐induced liver injury</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2009</year>;<volume>106</volume>(<issue>11</issue>):<fpage>4402</fpage>‐<lpage>4407</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.0813371106</pub-id>
<pub-id pub-id-type="pmid">19246379</pub-id>
</mixed-citation>
              </ref>
              <ref id="bcp15661-bib-0013">
                <label>13</label>
                <mixed-citation publication-type="journal" id="bcp15661-cit-0014"><string-name><surname>Bala</surname><given-names>S</given-names></string-name>, <string-name><surname>Petrasek</surname><given-names>J</given-names></string-name>, <string-name><surname>Mundkur</surname><given-names>S</given-names></string-name>, et al. <article-title>Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug‐induced, and inflammatory liver diseases</article-title>. <source>Hepatology</source>. <year>2012</year>;<volume>56</volume>(<issue>5</issue>):<fpage>1946</fpage>‐<lpage>1957</lpage>. doi:<pub-id pub-id-type="doi">10.1002/hep.25873</pub-id>
<pub-id pub-id-type="pmid">22684891</pub-id>
</mixed-citation>
              </ref>
              <ref id="bcp15661-bib-0014">
                <label>14</label>
                <mixed-citation publication-type="journal" id="bcp15661-cit-0015"><string-name><surname>Starkey Lewis</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Dear</surname><given-names>J</given-names></string-name>, <string-name><surname>Platt</surname><given-names>V</given-names></string-name>, et al. <article-title>Circulating microRNAs as potential markers of human drug‐induced liver injury</article-title>. <source>Hepatology</source>. <year>2011</year>;<volume>54</volume>(<issue>5</issue>):<fpage>1767</fpage>‐<lpage>1776</lpage>. doi:<pub-id pub-id-type="doi">10.1002/hep.24538</pub-id>
<pub-id pub-id-type="pmid">22045675</pub-id>
</mixed-citation>
              </ref>
              <ref id="bcp15661-bib-0015">
                <label>15</label>
                <mixed-citation publication-type="journal" id="bcp15661-cit-0016"><string-name><surname>Vliegenthart</surname><given-names>AD</given-names></string-name>, <string-name><surname>Shaffer</surname><given-names>JM</given-names></string-name>, <string-name><surname>Clarke</surname><given-names>JI</given-names></string-name>, et al. <article-title>Comprehensive microRNA profiling in acetaminophen toxicity identifies novel circulating biomarkers for human liver and kidney injury</article-title>. <source>Sci Rep</source>. <year>2015</year>;<volume>5</volume>(<issue>1</issue>):<elocation-id>15501</elocation-id>. doi:<pub-id pub-id-type="doi">10.1038/srep15501</pub-id><pub-id pub-id-type="pmid">26489516</pub-id></mixed-citation>
              </ref>
              <ref id="bcp15661-bib-0016">
                <label>16</label>
                <mixed-citation publication-type="journal" id="bcp15661-cit-0017"><string-name><surname>Ward</surname><given-names>J</given-names></string-name>, <string-name><surname>Kanchagar</surname><given-names>C</given-names></string-name>, <string-name><surname>Veksler‐Lublinsky</surname><given-names>I</given-names></string-name>, et al. <article-title>Circulating microRNA profiles in human patients with acetaminophen hepatotoxicity or ischemic hepatitis</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2014</year>;<volume>111</volume>(<issue>33</issue>):<fpage>12169</fpage>‐<lpage>12174</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.1412608111</pub-id>
<pub-id pub-id-type="pmid">25092309</pub-id>
</mixed-citation>
              </ref>
              <ref id="bcp15661-bib-0017">
                <label>17</label>
                <mixed-citation publication-type="journal" id="bcp15661-cit-0018"><string-name><surname>Thulin</surname><given-names>P</given-names></string-name>, <string-name><surname>Nordahl</surname><given-names>G</given-names></string-name>, <string-name><surname>Gry</surname><given-names>M</given-names></string-name>, et al. <article-title>Keratin‐18 and microRNA‐122 complement alanine aminotransferase as novel safety biomarkers for drug‐induced liver injury in two human cohorts</article-title>. <source>Liver Int</source>. <year>2014</year>;<volume>34</volume>(<issue>3</issue>):<fpage>367</fpage>‐<lpage>378</lpage>. doi:<pub-id pub-id-type="doi">10.1111/liv.12322</pub-id>
<pub-id pub-id-type="pmid">24118944</pub-id>
</mixed-citation>
              </ref>
              <ref id="bcp15661-bib-0018">
                <label>18</label>
                <mixed-citation publication-type="journal" id="bcp15661-cit-0019"><string-name><surname>Antoine</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Dear</surname><given-names>JW</given-names></string-name>, <string-name><surname>Lewis</surname><given-names>PS</given-names></string-name>, et al. <article-title>Mechanistic biomarkers provide early and sensitive detection of acetaminophen‐induced acute liver injury at first presentation to hospital</article-title>. <source>Hepatology</source>. <year>2013</year>;<volume>58</volume>(<issue>2</issue>):<fpage>777</fpage>‐<lpage>787</lpage>. doi:<pub-id pub-id-type="doi">10.1002/hep.26294</pub-id>
<pub-id pub-id-type="pmid">23390034</pub-id>
</mixed-citation>
              </ref>
              <ref id="bcp15661-bib-0019">
                <label>19</label>
                <mixed-citation publication-type="journal" id="bcp15661-cit-0020"><string-name><surname>López‐Riera</surname><given-names>M</given-names></string-name>, <string-name><surname>Conde</surname><given-names>I</given-names></string-name>, <string-name><surname>Castell</surname><given-names>JV</given-names></string-name>, <string-name><surname>Jover</surname><given-names>R</given-names></string-name>. <article-title>A novel MicroRNA signature for cholestatic drugs in human hepatocytes and its translation into novel circulating biomarkers for drug‐induced liver injury patients</article-title>. <source>Toxicol Sci</source>. <year>2020</year>;<volume>173</volume>(<issue>2</issue>):<fpage>229</fpage>‐<lpage>243</lpage>. doi:<pub-id pub-id-type="doi">10.1093/toxsci/kfz138</pub-id>
<pub-id pub-id-type="pmid">31198949</pub-id>
</mixed-citation>
              </ref>
              <ref id="bcp15661-bib-0020">
                <label>20</label>
                <mixed-citation publication-type="journal" id="bcp15661-cit-0021"><string-name><surname>Church</surname><given-names>RJ</given-names></string-name>, <string-name><surname>Kullak‐Ublick</surname><given-names>GA</given-names></string-name>, <string-name><surname>Aubrecht</surname><given-names>J</given-names></string-name>, et al. <article-title>Candidate biomarkers for the diagnosis and prognosis of drug‐induced liver injury: an international collaborative effort</article-title>. <source>Hepatology</source>. <year>2019</year>;<volume>69</volume>(<issue>2</issue>):<fpage>760</fpage>‐<lpage>773</lpage>. doi:<pub-id pub-id-type="doi">10.1002/hep.29802</pub-id>
<pub-id pub-id-type="pmid">29357190</pub-id>
</mixed-citation>
              </ref>
              <ref id="bcp15661-bib-0021">
                <label>21</label>
                <mixed-citation publication-type="journal" id="bcp15661-cit-0022"><string-name><surname>Russo</surname><given-names>MW</given-names></string-name>, <string-name><surname>Steuerwald</surname><given-names>N</given-names></string-name>, <string-name><surname>Norton</surname><given-names>HJ</given-names></string-name>, et al. <article-title>Profiles of miRNAs in serum in severe acute drug induced liver injury and their prognostic significance</article-title>. <source>Liver Int</source>. <year>2017</year>;<volume>37</volume>(<issue>5</issue>):<fpage>757</fpage>‐<lpage>764</lpage>. doi:<pub-id pub-id-type="doi">10.1111/liv.13312</pub-id>
<pub-id pub-id-type="pmid">27860186</pub-id>
</mixed-citation>
              </ref>
              <ref id="bcp15661-bib-0022">
                <label>22</label>
                <mixed-citation publication-type="journal" id="bcp15661-cit-0023"><string-name><surname>Moosa</surname><given-names>MS</given-names></string-name>, <string-name><surname>Maartens</surname><given-names>G</given-names></string-name>, <string-name><surname>Gunter</surname><given-names>H</given-names></string-name>, et al. <article-title>A randomized controlled trial of intravenous N‐acetylcysteine in the management of anti‐tuberculosis drug‐induced liver injury</article-title>. <source>Clin Infect Dis</source>. <year>2021</year>;<volume>73</volume>(<issue>9</issue>):<fpage>e3377</fpage>‐<lpage>e3383</lpage>. doi:<pub-id pub-id-type="doi">10.1093/cid/ciaa1255</pub-id>
<pub-id pub-id-type="pmid">32845997</pub-id>
</mixed-citation>
              </ref>
              <ref id="bcp15661-bib-0023">
                <label>23</label>
                <mixed-citation publication-type="journal" id="bcp15661-cit-0024"><string-name><surname>Rupprechter</surname><given-names>SAE</given-names></string-name>, <string-name><surname>Sloan</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Oosthuyzen</surname><given-names>W</given-names></string-name>, et al. <article-title>MicroRNA‐122 and cytokeratin‐18 have potential as a biomarkers of drug‐induced liver injury in European and African patients on treatment for mycobacterial infection</article-title>. <source>Br J Clin Pharmacol</source>. <year>2021</year>;<volume>87</volume>(<issue>8</issue>):<fpage>3206</fpage>‐<lpage>3217</lpage>. doi:<pub-id pub-id-type="doi">10.1111/bcp.14736</pub-id>
<pub-id pub-id-type="pmid">33432705</pub-id>
</mixed-citation>
              </ref>
              <ref id="bcp15661-bib-0024">
                <label>24</label>
                <mixed-citation publication-type="journal" id="bcp15661-cit-0025"><string-name><surname>Bakshi</surname><given-names>S</given-names></string-name>, <string-name><surname>Kaur</surname><given-names>M</given-names></string-name>, <string-name><surname>Saini</surname><given-names>N</given-names></string-name>, et al. <article-title>Altered expressions of circulating microRNAs 122 and 192 during antitubercular drug induced liver injury indicating their role as potential biomarkers</article-title>. <source>Hum Exp Toxicol</source>. <year>2021</year>;<volume>40</volume>(<issue>9</issue>):<fpage>1474</fpage>‐<lpage>1484</lpage>. doi:<pub-id pub-id-type="doi">10.1177/0960327121997975</pub-id>
<pub-id pub-id-type="pmid">33729026</pub-id>
</mixed-citation>
              </ref>
              <ref id="bcp15661-bib-0025">
                <label>25</label>
                <mixed-citation publication-type="journal" id="bcp15661-cit-0026"><string-name><surname>Vogt</surname><given-names>J</given-names></string-name>, <string-name><surname>Sheinson</surname><given-names>D</given-names></string-name>, <string-name><surname>Katavolos</surname><given-names>P</given-names></string-name>, et al. <article-title>Variance component analysis of circulating miR‐122 in serum from healthy human volunteers</article-title>. <source>PLoS ONE</source>. <year>2019</year>;<volume>14</volume>(<issue>7</issue>):<elocation-id>e0220406</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0220406</pub-id><pub-id pub-id-type="pmid">31348817</pub-id></mixed-citation>
              </ref>
              <ref id="bcp15661-bib-0026">
                <label>26</label>
                <mixed-citation publication-type="journal" id="bcp15661-cit-0027"><string-name><surname>Metushi</surname><given-names>I</given-names></string-name>, <string-name><surname>Uetrecht</surname><given-names>J</given-names></string-name>, <string-name><surname>Phillips</surname><given-names>E</given-names></string-name>. <article-title>Mechanism of isoniazid‐induced hepatotoxicity: then and now</article-title>. <source>Br J Clin Pharmacol</source>. <year>2016</year>;<volume>81</volume>(<issue>6</issue>):<fpage>1030</fpage>‐<lpage>1036</lpage>. doi:<pub-id pub-id-type="doi">10.1111/bcp.12885</pub-id>
<pub-id pub-id-type="pmid">26773235</pub-id>
</mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
